Risk of Severe Bronchospasm

• Mannitol, the active ingredient in Aridol, acts as a bronchoconstrictor and may cause severe bronchospasm.
• Bronchial challenge testing with this product is for diagnostic purposes only.
• Bronchial testing with this product should only be conducted by trained professionals under the supervision of a physician familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm.
• Medications (such as short acting inhaled beta-agonist) and equipment to treat severe bronchospasm must be present in the testing area.
• If severe bronchospasm occurs it should be treated immediately by administration of a short acting inhaled beta-agonist.
• Because of the potential for severe bronchoconstriction, the bronchial challenge testing with this product should not be performed in any patients with clinically apparent asthma or very low baseline pulmonary function tests (e.g., FEV1 < 1>